Method to Obtain Hematopoietic Stem Cells
None
Patent Number: US20110311492A1
Application Number: US13132283A
Inventor: Verfaillie, Catherine | Buckley, Shannon Mychel | Khurana, Satish
Priority Date: 1 Dec 2008
Priority Number: US20110311492A1
Application Date: 21 Jul 2011
Publication Date: 22 Dec 2011
IPC Current: A61K003512 | A61K003802 | A61K003818 | A61P000700 | C12N00050789
US Class: 4240937 | 435375 | 5140076 | 5140135
Title: MAINTENANCE/EXPANSION OF HSC's
Usefulness: MAINTENANCE/EXPANSION OF HSC's
Summary: The methods are useful for maintaining/expanding HSCs; preparing a composition; and treating a non-malignant blood disorder, a metabolic storage disorder, or cancer. The cell, composition, HSCs which have been contacted with the factors, and the factors are useful in medical therapy for treating a non-malignant blood disorder, a metabolic storage disorder, or cancer. The non-malignant blood disorder is selected from immunodeficiencies comprising severe combined immunodeficiency (SCID), Fanconi's anemia, aplastic anemia, or congenital hemoglobinopathy. The metabolic storage disease is Hurler's disease, Hunter's disease, or mannosidosis. Cancer is selected from hematological malignancies comprising acute leukemia, chronic leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome, or non-hematological cancer. The chronic leukemia is myeloid or lymphoid. The lymphoma is Hodgkin's or non-Hodgkin's lymphoma. The non-hematological cancer is breast carcinoma, colon carcinoma, neuroblastoma, or renal cell carcinoma (all claimed).
Novelty: Maintaining/expanding hematopoietic stem cells (HSCs) by contacting HSCs with exogenous factors, e.g. tissue factor pathway inhibitor (TFPI) or defensin related cryptdin 3 (DEFCR3) or its biologically active fragment or derivative
诊断/治疗
癌症/肿瘤
美国
